BACKGROUND AND OBJECTIVES: AKI is associated with short- and long-term mortality. However, the exact contribution of AKI complications to the burden of mortality and whether RRT has any beneficial effect on reducing mortality rates in critically ill AKI patients are unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a retrospective analysis using data from the Multiparameter Intelligent Monitoring in Intensive Care II project. A total of 18,410 adult patients were enrolled from four intensive care units from a university hospital from 2001 to 2008. RESULTS: Overall, 10,245 patients developed AKI. After adjustments, the odds ratios (ORs) for hospital mortality were 1.73 (95% confidence interval [95% CI], 1.52 to 1.98) for AKI stage 1, 1.88 (95% CI, 1.57 to 2.25) for stage 2, and 2.89 (95% CI, 2.41 to 3.46) for stage 3. Totals of 33%, 59%, and 70% of the excess mortality rates associated with AKI stages 1, 2, and 3, respectively, were attenuated by the inclusion of each AKI-related complication in the model. The main burden of excess hospital mortality associated with AKI was attenuated by metabolic acidosis and cumulative fluid balance. Long-term mortality was not attenuated by any of the associated complications. Next, we used two different approaches to explore the associations between RRT, AKI complications, and hospital mortality: multivariate analysis and propensity score matching. In both approaches, the sensitivity analysis for RRT was associated with a better hospital survival in only the following AKI-related subgroups: hyperkalemia (OR, 0.55; 95% CI, 0.35 to 0.85), metabolic acidosis (OR, 0.70; 95% CI, 0.53 to 0.92), cumulative fluid balance >5% of body weight (OR, 0.60; 95% CI, 0.40 to 0.88), and azotemia (OR, 0.57; 95% CI, 0.40 to 0.81). CONCLUSIONS: A majority of the excess risk of mortality associated with AKI was attenuated by its fluid volume and metabolic complications, particularly in severe AKI. In addition, this study demonstrated that RRT is associated with a better outcome in patients with AKI-related complications.
BACKGROUND AND OBJECTIVES: AKI is associated with short- and long-term mortality. However, the exact contribution of AKI complications to the burden of mortality and whether RRT has any beneficial effect on reducing mortality rates in critically ill AKI patients are unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a retrospective analysis using data from the Multiparameter Intelligent Monitoring in Intensive Care II project. A total of 18,410 adult patients were enrolled from four intensive care units from a university hospital from 2001 to 2008. RESULTS: Overall, 10,245 patients developed AKI. After adjustments, the odds ratios (ORs) for hospital mortality were 1.73 (95% confidence interval [95% CI], 1.52 to 1.98) for AKI stage 1, 1.88 (95% CI, 1.57 to 2.25) for stage 2, and 2.89 (95% CI, 2.41 to 3.46) for stage 3. Totals of 33%, 59%, and 70% of the excess mortality rates associated with AKI stages 1, 2, and 3, respectively, were attenuated by the inclusion of each AKI-related complication in the model. The main burden of excess hospital mortality associated with AKI was attenuated by metabolic acidosis and cumulative fluid balance. Long-term mortality was not attenuated by any of the associated complications. Next, we used two different approaches to explore the associations between RRT, AKI complications, and hospital mortality: multivariate analysis and propensity score matching. In both approaches, the sensitivity analysis for RRT was associated with a better hospital survival in only the following AKI-related subgroups: hyperkalemia (OR, 0.55; 95% CI, 0.35 to 0.85), metabolic acidosis (OR, 0.70; 95% CI, 0.53 to 0.92), cumulative fluid balance >5% of body weight (OR, 0.60; 95% CI, 0.40 to 0.88), and azotemia (OR, 0.57; 95% CI, 0.40 to 0.81). CONCLUSIONS: A majority of the excess risk of mortality associated with AKI was attenuated by its fluid volume and metabolic complications, particularly in severe AKI. In addition, this study demonstrated that RRT is associated with a better outcome in patients with AKI-related complications.
Authors: F Perry Wilson; Wei Yang; Carlos A Machado; Laura H Mariani; Yuliya Borovskiy; Jeffrey S Berns; Harold I Feldman Journal: Clin J Am Soc Nephrol Date: 2014-03-20 Impact factor: 8.237
Authors: Tibor Fülöp; Minesh B Pathak; Darren W Schmidt; Zsolt Lengvárszky; Julio P Juncos; Christopher J Lebrun; Harjeet Brar; Luis A Juncos Journal: ASAIO J Date: 2010 Jul-Aug Impact factor: 2.872
Authors: Tariq Ali; Izhar Khan; William Simpson; Gordon Prescott; John Townend; William Smith; Alison Macleod Journal: J Am Soc Nephrol Date: 2007-02-21 Impact factor: 10.121
Authors: Victor F Seabra; Ethan M Balk; Orfeas Liangos; Marie Anne Sosa; Miguel Cendoroglo; Bertrand L Jaber Journal: Am J Kidney Dis Date: 2008-06-18 Impact factor: 8.860
Authors: Jeremie M Lever; Travis D Hull; Ravindra Boddu; Mark E Pepin; Laurence M Black; Oreoluwa O Adedoyin; Zhengqin Yang; Amie M Traylor; Yanlin Jiang; Zhang Li; Jacelyn E Peabody; Hannah E Eckenrode; David K Crossman; Michael R Crowley; Subhashini Bolisetty; Kurt A Zimmerman; Adam R Wende; Michal Mrug; Bradley K Yoder; Anupam Agarwal; James F George Journal: JCI Insight Date: 2019-01-24
Authors: Etienne Macedo; Azra Bihorac; Edward D Siew; Paul M Palevsky; John A Kellum; Claudio Ronco; Ravindra L Mehta; Mitchell H Rosner; Michael Haase; Kianoush B Kashani; Erin F Barreto Journal: Eur J Intern Med Date: 2020-06-30 Impact factor: 4.487
Authors: Gabrielle E Hatton; Reginald E Du; Claudia Pedroza; Shuyan Wei; John A Harvin; Kevin W Finkel; Charles E Wade; Lillian S Kao Journal: J Am Coll Surg Date: 2019-09-20 Impact factor: 6.113